This Article Full Text Full Text (PDF) All Versions of this Article: 38/12/3302    most recent STROKEAHA.107.485144v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marler, J. R. Search for Related Content PubMed PubMed Citation Articles by Marler, J. R. Related Collections AHA Statements and Guidelines Other Stroke

(Stroke. 2007;38:3302.)
© 2007 American Heart Association, Inc.

Special Reports

NINDS Clinical Trials in Stroke

Lessons Learned and Future Directions

From the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Rockville, Md.

Correspondence to John R. Marler, MD, Associate Director for Clinical Trials, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd, Rm 2216, Rockville, MD 20892. E-mail marlerj{at}ninds.nih.gov

Abstract

Since 1977 the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) has sponsored 28 phase 3 trials to evaluate treatments of stroke, which when all completed will have randomized a total of 44 862 patients in the United States and other countries. NINDS stroke clinical trials have been successful in finding beneficial and cost-effective treatments for cerebrovascular disease. Future trials are likely to be larger and have simpler designs which allow for the inclusion of more patients and which collect less data for each patient. In addition, measures of cognitive outcomes, particularly timed tests of executive function, disability scales, and quality-of-life outcomes will become more common. The stroke research community can take pride in the solid base of evidence that has been built over the past 2 decades. If we continue to follow the discoveries of science, continue to create new trial methodology, and increase participation in clinical trials, significant advances in the treatment of cerebrovascular disease will continue.

Key Words: clinical trials • stroke

This article has been cited by other articles:

				M.-K. Sun, J. Hongpaisan, and D. L. Alkon Postischemic PKC activation rescues retrograde and anterograde long-term memory PNAS, August 25, 2009; 106(34): 14676 - 14680. [Abstract] [Full Text] [PDF]

				W. N. Kernan, C. M. Viscoli, D. DeMarco, B. Mendes, K. Shrauger, J. L. Schindler, J. C. McVeety, A. Sicklick, D. Moalli, P. Greco, et al. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs) Neurology, April 14, 2009; 72(15): 1345 - 1351. [Abstract] [Full Text] [PDF]

				E. C. Leira, A. Ahmed, D. L. Lamb, H. M. Olalde, R. C. Callison, J. C. Torner, H. P. Adams Jr, and for the AIRDOC study Investigators Extending Acute Trials to Remote Populations: A Pilot Study During Interhospital Helicopter Transfer Stroke, March 1, 2009; 40(3): 895 - 901. [Abstract] [Full Text] [PDF]

				J. G. Merino Untangling Vascular Cognitive Impairment Stroke, March 1, 2008; 39(3): 739 - 740. [Full Text] [PDF]